Working… Menu

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study (CHEMO-T)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01719835
Recruitment Status : Active, not recruiting
First Posted : November 1, 2012
Last Update Posted : March 15, 2018
Cancer Research UK
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

Tracking Information
First Submitted Date  ICMJE April 12, 2012
First Posted Date  ICMJE November 1, 2012
Last Update Posted Date March 15, 2018
Study Start Date  ICMJE March 2012
Actual Primary Completion Date November 30, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 30, 2012)
complete response rate (CR/CRu) [ Time Frame: approximately 20 weeks after randomisation ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01719835 on Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 30, 2012)
  • Toxicity [ Time Frame: approximately 20 weeks after randomisation ]
    using Common Terminology Criteria for Adverse Events (CTCAE)v4.0
  • Overall Survival [ Time Frame: 1 and 2 years ]
  • Progression Free survival [ Time Frame: 1 and 2 years ]
  • Metabolic Complete Response Rate [ Time Frame: approximately 20 weeks after randomisation ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
Official Title  ICMJE CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study
Brief Summary This is a randomised, open-label phase II study comparing GEM-P chemotherapy (experimental arm) with CHOP (control arm) in previously untreated T-cell lymphoma. Eligible patients will be randomised 1:1 between 4-weekly GEM-P or 3-weekly CHOP chemotherapy.
Detailed Description


T-cell lymphoma is an aggressive rare subset of Non-Hodgkin lymphoma (NHL) comprising several different subtypes of disease within this group. No standard first-line treatment exists for T-cell lymphoma as published series are small, with heterogeneous populations and often retrospective.

Protocol Synopsis, Study Period: 5 years



• To compare the complete response rate of GEM-P with CHOP chemotherapy in the first line treatment of patients with T-Cell Lymphoma.


To investigate, between both arms:

  • Rate of metabolic complete response
  • Toxicity of treatment
  • Overall survival (OS)
  • Progression Free Survival (PFS)


• Investigate impact of International Prognostic Index (IPI) on the outcomes response rate, PFS and OS

Study Design:

A randomised multi-centre open-label phase II study

Indication: Previously untreated T-Cell lymphoma No of Participants: 186 (93 patients in each arm)

Main Eligibility Criteria:

  • Histologically proven T-cell lymphoma of the following subtypes:
  • Peripheral T-cell lymphoma NOS
  • Systemic Anaplastic large cell lymphoma (ALCL) Anaplastic lymphoma kinase (ALK) negative cases only
  • Angioimmunoblastic T-cell lymphoma
  • Hepatosplenic gamma/ delta T-cell lymphoma
  • Enteropathy-associated T-cell lymphoma
  • Bulky Stage I, Stage II, III or IV
  • No prior chemotherapy regimen
  • Patients aged 18 years or over.
  • WHO performance status 0,1 or 2
  • Adequate organ function:
  • No Central Nervous System(CNS) or leptomeningeal involvement with lymphoma
  • No treatment for lymphoma within 4 weeks of commencing trial therapy
  • No known HIV, active Hepatitis B or C infection


CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone every 21 days. GEM-P: gemcitabine, methylprednisolone, cisplatin every 28 days.

Assessment Schedule:

  • Patients will be reviewed at baseline and prior to each scheduled dose of treatment for toxicity
  • Radiological tumour assessment will be done with CT scan after every 2 cycles in Arm A and after cycle 1, 3 and 4 in Arm B
  • PET/CT scan will be performed at baseline and upon completion of treatment..
  • Follow up after completion of treatment will be 3, 6, 9, 12, 18, 24 months then annually for 5 years in total. CT scan will be performed at 3 & 12 months.
  • Following disease progression patients will be followed for survival every 3 months until death
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Peripheral T-cell Lymphoma NOS
  • Anaplastic Large Cell Lymphoma, ALK-Negative
  • Angioimmunoblastic T-cell Lymphoma
  • Hepatosplenic Gamma/ Delta T-cell Lymphoma
  • Enteropathy-Associated T-Cell Lymphoma
Intervention  ICMJE
  • Drug: Cyclophosphamide
    750mg/m2 IV every 21 days
  • Drug: Gemcitabine
    1000mg/m2 IV Days 1, 8, 15 every 28 days
  • Drug: Doxorubicin
    50mg/m2 IV every 21 days
  • Drug: Vincristine
    1.4mg/m2 (max 2mg) IV every 21 days
  • Drug: Prednisolone
    100mg PO Days 1-5 every 21 days
  • Drug: methylprednisolone
    1000mg oral or IV Days 1-5 every 28 days
  • Drug: Cisplatin
    100mg/m2 IV Day 15 every 28 days
Study Arms  ICMJE
  • Experimental: Chemotherapy GEM-P
    Gemcitabine, Methylprednisolone, Cisplatin
    • Drug: Gemcitabine
    • Drug: methylprednisolone
    • Drug: Cisplatin
  • Active Comparator: Chemotherapy CHOP
    Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
    • Drug: Cyclophosphamide
    • Drug: Doxorubicin
    • Drug: Vincristine
    • Drug: Prednisolone
Publications * Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, Attygalle AD, Zerizer I, Sharma B, Chua S, Begum R, Chau I, Johnson P, Ardeshna KM, Hawkes EA, Macheta MP, Collins GP, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol. 2018 May;5(5):e190-e200. doi: 10.1016/S2352-3026(18)30039-5.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: March 13, 2018)
Original Estimated Enrollment  ICMJE
 (submitted: October 30, 2012)
Estimated Study Completion Date  ICMJE August 2022
Actual Primary Completion Date November 30, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Previously untreated, histologically proven T-cell Lymphoma (any of the following):

  • Peripheral T-cell lymphoma Not Otherwise Specified (PTCL NOS)
  • Systemic Anaplastic large cell lymphoma (ALCL) ALK negative cases only
  • Angioimmunoblastic T-cell lymphoma
  • Hepatosplenic gamma/ delta T-cell lymphoma
  • Enteropathy-associated T-cell lymphoma (EATL)

    • Bulky stage I not being considered for reduced chemotherapy plus involved field radiotherapy or stage II, III or IV.
    • Patient is male or female, and ≥18 years of age on the day of signing informed consent.
    • WHO performance status 0, 1 or 2.
    • Cross sectional imaging from a baseline contrast enhanced CT should show at least one measurable disease site that is at least 2 cm in longest diameter and measurable in two perpendicular dimensions with or without corresponding Fluorodeoxyglucose(FDG) avid lesions.
    • Adequate cardiac function; formal assessment of left ventricular ejection fraction is only required if clinically indicated (a baseline echocardiogram should be done for patients with either hypertension, age > 60 years or history of cardiac disease)
    • Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.0x109/l; white blood cell count ≥ 3x109/l; platelets ≥ 100x109/l; haemoglobin (Hb) ≥ 9g/dl (can be post-transfusion), unless deemed disease related
    • Adequate renal function: calculated creatinine clearance ≥50ml/minute.
    • Adequate liver function: serum bilirubin ≤1.5x Upper limit of normal (ULN); Alanine transaminase/Aspartate transaminase (ALT/AST) ≤2.5x ULN; ALP ≤3x ULN (in the absence of liver metastases). If liver metastases are present, ALT, AST or Alkaline phosphatase (ALP) ≤5x ULN are permitted. Isolated hyperbilirubinaemia due to Gilbert's disease is acceptable
    • Female patient of childbearing potential must have a negative serum or urine β-human chorionic gonadotropin(hCG)pregnancy test at baseline.
    • Written informed consent must be obtained prior to start of study treatments. Scans and bone marrow biopsies performed within 4 weeks of commencement of therapy will be acceptable provided they have been performed according to study requirements.
    • Patient agreeable to use contraception for the period of study treatment and up to 12 months after the last dose of study drugs.

Exclusion Criteria:

  • Documented or symptomatic central nervous system involvement or leptomeningeal disease.
  • Patients with no measurable disease on the contrast enhanced CT scan at baseline.
  • Any other clinically significant disease or co-morbidity which may adversely affect the safe delivery of treatment within this trial.
  • Any other malignancies diagnosed or treated within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).
  • Treatment with another investigational agent within 30 days of commencing study treatment.
  • Known positive tests for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or active hepatitis B infection.
  • Patient is pregnant or breastfeeding, or expecting to conceive or father children within one year of finishing study treatment.
  • Patients with poorly controlled diabetes mellitus
  • Hypersensitivity or contraindication to any of the study drugs as stated in the Summaries of product characteristics(SmPCs)for each of the study drugs. Patients with previous cardiac infarct but satisfactory cardiac function may be allowed at the discretion of Chief Investigator.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01719835
Other Study ID Numbers  ICMJE RMH CCR: 3549
2011-004146-18 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Royal Marsden NHS Foundation Trust
Study Sponsor  ICMJE Royal Marsden NHS Foundation Trust
Collaborators  ICMJE Cancer Research UK
Investigators  ICMJE
Principal Investigator: David Cunningham, MD FRCP Royal Marsden NHS Foundation Trust
PRS Account Royal Marsden NHS Foundation Trust
Verification Date March 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP